Timing the Target: Exploring the Circadian Transcriptome of Biologic Therapies in Asthma.
Background: Many of the immune pathways involved in asthma or in asthma treatment show circadian or diurnal variation. Understanding this variation can aid in biomarker discovery and/or therapy optimization. Objective: To evaluate if receptors, cytokines, and their pathways (n=46) targeted by currently approved biologics show significant diurnal rhythmicity and to identify their peak expression time. Methods: We used longitudinal bulk RNA sequencing datasets (discovery/replication cohorts: GSE113883 and GSE223613) and one microarray file (GSE39445) for cross-platform replication/validation. First, we used 16 canonical clock genes (including CLOCK, BMAL1, REV-ERB-beta) as positive controls to explore rhythmicity in each cohort. Thereafter, we evaluated if any targets of currently approved biologics or their corresponding receptors showed significant diurnal variation. For significant genes (Benjamini-Hochberg FDR<0.05), we estimated the baseline average, phase, peak-time of expression across the 24-hour day using clock time and quantified the cross-cohort consistency in the peak time of expression across the cohorts. Results: These cohorts included 453 longitudinal samples collected every two to four hours over a 24-28h cycle. Twelve (75%) of 16 evaluable clock genes showed significant rhythmicity. Only 34 of 46 (74%) asthma-related genes were evaluable across two or more cohorts. Of these 34 genes, 23 (68%) showed significant variation. Across all cohorts, the most preserved rhythmically expressed targets included many pathways or targets of monoclonal antibodies that are currently approved or in development: GATA3 and STAT6, master regulators of type 2 inflammation and IL4/IL13 signaling; chemokines, including the neutrophil chemoattractant, CXCL8; IL-5RA, benralizumab's target; FcRE1, suppressed by omalizumab; and IL1RL1(ST2) in clinical trials. Conclusion: Many therapeutic targets in asthma show significant diurnal rhythmicity. Future studies on how dosing time affects their therapeutic effectiveness while minimizing side effects are needed.
Authors
- Frank A. J. L. Scheer (ORCID: https://orcid.org/0000-0002-2014-7582)
- Ayobami T. Akenroye (ORCID: https://orcid.org/0000-0002-1909-1470)
- Scott T. Weiss (ORCID: https://orcid.org/0000-0001-7196-303X)
- Vincent J. Carey (ORCID: https://orcid.org/0000-0003-4046-0063)
Institutions
- Brigham and Women's Hospital (US)
Publication Details
- Journal
- medRxiv
- Published
- 2026-11-18
- DOI
- https://doi.org/10.64898/2026.11.16.26368198
- Primary Topic
- Asthma and respiratory diseases
- Type
- preprint
Funders
- Brigham and Women's Hospital
- Massachusetts General Hospital